A randomized, double-blinded controlled trial (RCT) of a new whole IgG, equine antivenom compared to the currently used F(ab’)2 CSL taipan antivenom, for the treatment of Papuan taipan (Oxyuranus scutellatus) envenoming in Papua New Guinea.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1033977

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Snakebite is very common in Papua New Guinea (PNG), and many bites are caused by the Papuan taipan, a highly venomous snake found in the southern PNG savannah's. Current antivenom is expensive (US$1500) and many patients do not receive optimal treatment. We will conduct a randomised controlled trial of a new, low cost taipan antivenom developed specifically for PNG. The safety and efficacy of the new antivenom is compared to the existing product to determine if it is a suitable alternative.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $1,453,073.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Toxicology (incl. Clinical Toxicology)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

acute care | antibody therapy | clinical effectiveness | clinical pharmacology | clinical trial | immunotherapy | indigenous | statistics | toxins | venom

Related Links